drugset / Trial / NCT00915915

Inhibition of Ovulation and Pharmacokinetics of Transdermal Ethinylestradiol (EE) and Gestodene (GSD)

NCT00915915

Phase 2 Completed 108 enrolled Bayer
RandomizedParallel-groupOpen-labelTreatment

Summary

Investigation of two transdermal hormone patch formulations for contraception regarding inhibition of ovulation over a period of 3 treatment cycles in healthy young female volunteers

Timeline

Start
2009-06
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Gestodene Small molecule 1.05 mg Other
Subject Gestodene Small molecule 2.1 mg Other
Subject ethinyl estradiol Small molecule 0.55 mg Other

Indications